EXETER,
N.H., Nov. 1, 2023 /PRNewswire/ -- Vapotherm,
Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced
that it will release financial results for the third quarter of
2023 after the close of trading on Wednesday, November 8, 2023. Vapotherm's
management team will host a conference call beginning at
4:30 p.m. ET to discuss the financial
results and recent business developments.
To listen to the conference call on your telephone, please dial
+1 (888) 390-0546 for North American callers approximately ten
minutes prior to the start time and reference conference code
32204171. To listen to a live webcast, please visit the Investors
section of the Vapotherm website at:
http://investors.vapotherm.com/events-and-presentations/events. The
webcast replay will be available on the Vapotherm website for 12
months following completion of the call. A replay of this
conference call will be available by telephone through November 15, 2023 by dialing +1 (888) 390-0541 in
North America. The replay access
code is 204171.
Website Information
Vapotherm routinely posts important information for investors on
the Investor Relations section of its
website, http://investors.vapotherm.com/. Vapotherm intends to
use this website as a means of disclosing material, non-public
information and for complying with Vapotherm's disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the Investor Relations section of Vapotherm's website, in
addition to following Vapotherm's press releases, Securities and
Exchange Commission ("SEC") filings, public conference calls,
presentations and webcasts. The information contained on, or that
may be accessed through, Vapotherm's website is not incorporated by
reference into, and is not a part of, this document.
About Vapotherm
Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and
manufacturer of advanced respiratory technology based in
Exeter, New Hampshire, USA. The
Company develops innovative, comfortable, non-invasive technologies
for respiratory support of patients with chronic or acute breathing
disorders. Over 4.0 million patients have been treated with the use
of Vapotherm high velocity therapy® systems. For more information,
visit www.vapotherm.com.
Vapotherm high velocity therapy is mask-free non-invasive
respiratory support and is a front-line tool for relieving
respiratory distress—including hypercapnia, hypoxemia, and dyspnea.
It allows for the fast, safe treatment of undifferentiated
respiratory distress with one tool. The HVT 2.0 and Precision Flow
systems' mask-free interface delivers optimally conditioned
breathing gases, making it comfortable for patients and reducing
the risks and care complexities associated with mask therapies.
While being treated, patients can talk, eat, drink and take oral
medication.
Investor Relations Contacts:
John Landry, SVP & CFO,
ir@vtherm.com, +1 (603) 658-0011
View original content to download
multimedia:https://www.prnewswire.com/news-releases/vapotherm-to-report-third-quarter-2023-financial-results-301972922.html
SOURCE Vapotherm, Inc.
